Heart attack

December 19, 2017

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMSFN] encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 19/December/2017, 10.31 pm,

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
December 19, 2017

Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 19/December/2017, 10.17  pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
December 17, 2017

Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 17/December/2017,  11.03 pm

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
December 16, 2017

Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS,  16/December/2017, 11.49 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, […]